Balchem to acquire Kappa Bioscience for $338M; accretive to EPS in 2022

BALCHEM CORP

Enterprise value of NOK 3.175B (~$338M); EV/EBITDA multiple of 18x on 2022 forecast.
Kappa's FY2022 forecast revenues ~NOK 500M (~$53M) with strong growth and margin profile.
Additional earn-out potential of 0% to 16% of enterprise value in 2024 based on performance.
Closing expected Q2 2022; financed via existing revolver and cash on hand.
Deal expected to be accretive to Balchem's adjusted EPS in 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.